Dr. Vineeth K. Sukrithan, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 130
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.138763
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 130
- Services billed
- 304
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 318 | 120 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 50 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 22 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Columbus, OH | 82 |
| Mekinist (trametinib dimethyl sulfoxide) | 33 |
| Tafinlar (dabrafenib mesylate) | 32 |
| Retevmo (selpercatinib) | 24 |
| Ondansetron Hcl Other prescribers in Columbus, OH | 24 |
| Dexamethasone Other prescribers in Columbus, OH | 20 |
| Amlodipine Besylate Other prescribers in Columbus, OH | 19 |
| Klor-Con M20 (potassium chloride) Other prescribers in Columbus, OH | 15 |
| Hydroxyzine Hcl Other prescribers in Columbus, OH | 14 |
| Spironolactone Other prescribers in Columbus, OH | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $7,528 in total to this clinician.
| Lantheus Medical Imaging, Inc. | $4,778 |
|---|---|
| Exelixis Inc. | $2,750 |
| Honoraria | $4,778 |
|---|---|
| Speaking at a medical education program | $2,750 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lantheus Medical Imaging, Inc. Nov 6, 2025 | Honoraria | $4,778 |
| Exelixis Inc. Mar 28, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $825 |
| Exelixis Inc. Jul 25, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $825 |
| Exelixis Inc. Nov 13, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $825 |
| Exelixis Inc. Dec 18, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $275 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $136,432 in research payments for these studies, mostly to the institutions running them.
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company · Active, not recruiting · NCT03157128 - A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company · Completed · NCT05241834 - A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Eli Lilly and Company · Active, not recruiting · NCT04211337
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.